Objective: To analyze different clinical features from patients with chronic hepatitis B between HBeAg negative and positive.
Methods: 354 patients with chronic hepatitis B (124 cases with HBeAg positive and 230 cases with HBeAg negative) were enrolled into this retrospective investigation. Comparisons were conducted according to their demographic, liver biochemical, virological characters and clinical diagnosis types.
Results: (1) patients with chronic hepatitis B in HBeAg negative group have older age; moderate and severe chronic hepatitis occupied a lower proportion (P = 0.007 and 0.014). But fulminant hepatitis had a higher proportion (P = 0.008). (2) ALT, ALB, PTA and HBV DNA load of HBeAg negative group were lower than that of HBeAg positive group, but TBil in HBeAg negative group was higher; AST had no statistical significance between two groups. (3) In high HBV DNA load group ( > 10(5) copies/ml), HBeAg negative group had a lower proportion than HBeAg positive group (37.4% vs 55.6%, P = 0.001).
Conclusion: HBeAg-negative patients compared with HBeAg-positive patients had older age, lower serum HBV DNA level and other characteristics; HBeAg-negative patients maybe had serious disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Cost-effectiveness of monitoring and liver cancer surveillance among patients with inactive chronic hepatitis B.
PLoS One
January 2025
Department of Surgery, Asian Liver Center, Stanford University School of Medicine, Stanford, California, United States of America.
Patients with chronic hepatitis B infection (CHB) have an increased risk for death from liver cirrhosis and hepatocellular carcinoma (HCC). In the United States, only an estimated 37% of adults with chronic hepatitis B diagnosis without cirrhosis receive monitoring with at least an annual alanine transaminase (ALT) and hepatitis B deoxyribonucleic acid (DNA), and an estimated 59% receive antiviral treatment when they develop active hepatitis or cirrhosis. A Markov model was used to calculate the costs, health impact and cost-effectiveness of increased monitoring of adults with HBeAg negative inactive or HBeAg positive immune tolerant CHB who have no cirrhosis or significant fibrosis and are not recommended by the current American Association for the Study of Liver Diseases (AASLD) clinical practice guidelines to receive antiviral treatment, and to assess whether the addition of HCC surveillance would be cost-effective.
View Article and Find Full Text PDFUsefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B.
J Gastroenterol
January 2025
Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Background: Hepatitis B virus (HBV) RNA is an important serum biomarker of hepatic covalently closed circular DNA (cccDNA) transcriptional activity; however, its clinical characteristics remain unclear. This study evaluated the clinical utility of HBV RNA levels in patients with chronic hepatitis B (CHB).
Methods: We studied 87 CHB patients with serum HBV DNA levels ≥ 5.
C-X-C chemokine receptor type 5CD8 T cells as immune regulators in hepatitis Be antigen-positive chronic hepatitis B under interferon-alpha treatment.
World J Gastroenterol
January 2025
Institute of Hepatology and Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China.
Background: C-X-C chemokine receptor type 5 (CXCR5)CD8 T cells represent a unique immune subset with dual roles, functioning as cytotoxic cells in persistent viral infections while promoting B cell responses. Despite their importance, the specific role of CXCR5CD8 T cells in chronic hepatitis B (CHB), particularly during interferon-alpha (IFN-α) treatment, is not fully understood. This study aims to elucidate the relationship between CXCR5CD8 T cells and sustained serologic response (SR) in patients undergoing 48 weeks of pegylated IFN-α (peg-IFN-α) treatment for CHB.
View Article and Find Full Text PDFHigher Relapse Rate in HBeAg-negative Patients After Cessation of Tenofovir Alafenamide Compared to Entecavir or Tenofovir Disoproxil Fumarate.
Am J Gastroenterol
January 2025
Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taiwan.
Objectives: There is limited information comparing the off-therapy relapse rates of patients discontinued tenofovir alafenamide (TAF) to those stopping entecavir or tenofovir disoproxil fumarate (TDF).
Methods: A total of 805 HBeAg-negative patients without cirrhosis receiving entecavir (n=406), TDF (n=260) or TAF (n=139) were enrolled. Propensity-score (PS) matching method was applied to eliminate the significant differences in clinical characteristics.
The salivary microbiome and oral health status in HBeAg-negative chronic hepatitis B.
J Dent Sci
December 2024
Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden.
Background/purpose: Dysbiosis of oral microbiota has been reported in late stage of chronic hepatitis B (CHB) infection with cirrhosis. CHB is characterized by the constant virus-induced liver injury which may lead to liver cirrhosis and hepatocellular carcinoma (HCC). However, some patients show normal liver function without antiviral treatment, associating with favourable prognosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!